RxDoctor Payments Data

Lauren Pine, DO

Family Medicine · Huntington Station, NYNPI 1679138663

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 79 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$724
  • AstraZeneca$454
  • Sumitomo Pharma America, Inc.$174
  • Merck$163
  • Exact Sciences$109
  • Lilly USA, LLC$79
  • plus $454 from 11 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$92,377
Medicare patients
267
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$35,549
MounjaroTirzepatide23$22,265
Levothyroxine Sodium158$3,848
SynthroidLevothyroxine Sodium28$2,281
Atorvastatin Calcium141$1,491
Escitalopram Oxalate85$1,354
Valsartan41$1,348
Rosuvastatin Calcium85$1,192
Metoprolol Succinate52$1,002
Pantoprazole Sodium36$841
Bupropion XlBupropion Hcl25$715
Olmesartan Medoxomil18$628
Gabapentin30$621
Fluticasone Propionate45$594
Losartan Potassium64$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$724$35,54937 claims
Lilly USA, LLCMounjaro$79$22,26523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Huntington Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →